CSL LIMITED analysts consensus, targets, ratings and recommendations | Australian Stock Exchange: CSL | Australian Stock Exchange IG is not a financial advisor and all services are provided on an execution only basis.This website is owned and operated by IG Markets Limited. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.Go long or short on thousands of international stocks.Find out what charges your trades could incur with our transparent fee structure.Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.Stay on top of upcoming market-moving events with our customisable economic calendar.IG does not issue advice, recommendations or opinion in relation to acquiring, holding or disposing of our products. Free forex prices, toplists, indices and lots more. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. CSL Share Price View share performance over a selected period of time and access an Investment Calculator as well as Historical Prices. At CSL, Corporate Responsibility is about conducting our business ethically.
UBS is sticking to its “buy” call on CSL.The sharp rise in the unemployed in the US is likely to spur more donors to turn up at its collection centres (donors get paid in the US).However, UBS believes that costs will continue to climb due to higher collection fees.
Our exceptionally strong performance is a result of the focused execution of our strategy.
The general expectation appears to be that while the biotech will report strong earnings in FY20, profits are set to come under pressure in FY21 as a result of the coronavirus pandemic..
View share performance over a selected period of time and access an Investment Calculator as well as Historical Prices.
The CSL share price dipped 0.6% to $326.97 during lunch time trade when the top 200 stock index gained 0.5% in value. So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered! Innovation has been in the DNA of CSL since our beginning in 1916
ATM Stock Research CSL Limited – Technical Analysis Summary- CSL is a global biotechnology company that was listed on ASX at $2.30 per share back in June 1994. 2021 earnings weakness potential weighs on the biotech. For more information please see our The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214Brendon’s passion for shares started by accident in 2003 and he has worked in various roles around capital markets ever since as a trader, stock analyst and markets reporter with the Australian Financial Review.
Touch device users, explore by touch or with swipe gestures. Consequently any person acting on it does so entirely at their own risk.
Today’s CSL share price, stock chart and announcements. Find the investing style that's right for you. You do not own or have any interest in the underlying asset. CSL’s blood collection centres are largely located in that country.The impact of this is CSL’s earnings per share (EPS) will be lower than consensus estimates for FY21, added Morgan Stanley.What’s also notable is that the company’s costs are rising due to higher donor fees and advertising.Morgan Stanley’s recommendation on CSL is “equal-weight” (which means “hold”) with a price target of $288 a share.But not everyone shares this unenthusiastic view of ASX’s largest stock.
Visit this page to see all of our current news releases For the year ending March 2019 CSL Finance has declared an equity dividend of 20.00% amounting to Rs 2 per share. The results it reported on Wednesday for 2019 sent the share price up more than 6 per cent - despite the fact it … The Motley Fool Australia operates under AFSL 400691.
ET on The Wall Street Journal Hong Kong Shares Rally on Stimulus Hopes, Japan Edges Up Dividends to shareholders reported in U.S. dollars. Even so, UBS has retained its Buy rating and 12-month price target of $331 on the stock.CSL finished Wednesday’s session at ~$270 per share.The biotech itself noted that its all-important plasma collections would be impacted by the pandemic.